The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials.
This paper describes the natural history of the clinical syndrome of Alzheimer's disease (AD) including the cognitive deficit, the neuropsychiatric symptoms, impact on daily functioning, risk factors, medical complications and impact on the use of health-care resources. The clinical presentation of the disease varies greatly from the prodrome through end stage; instruments used to quantify the severity of each aspect of the disease have been developed and are described along with their use in clinical drug trials. Drug treatments for AD are usually developed by first showing a positive effect on the cognitive deficit, with later studies investigating drug effects on other clinical aspects of the disease.
Mohs
R C
RC
Eli Lilly and Company, Indianapolis, IN 46285, USA. mohsri@lilly.com
D000544:Alzheimer Disease / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D002986:Clinical Trials as Topic / Q000379:methods*; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000523:psychology; D006801:Humans; D008569:Memory Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000523:psychology; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000523:psychology; D009483:Neuropsychological Tests; D012107:Research Design; D012307:Risk Factors